(Q33183322)

23 July 2017

title

Retreatment with dose-dense weekly cisplatin after previous cisplatin chemotherapy is not complicated by significant neuro-toxicity (English)

1 reference

23 July 2017

1 reference

1 reference

van den Bent MJ

1

1 reference

23 July 2017

van Putten WL

2

1 reference

23 July 2017

Hilkens PH

3

1 reference

23 July 2017

de Wit R

4

1 reference

23 July 2017

van der Burg ME

5

1 reference

23 July 2017

publication date

1 February 2002

1 reference

European Journal of Cancer

23 July 2017

published in

1 reference

23 July 2017

volume

38

1 reference

23 July 2017

issue

3

1 reference

23 July 2017

page(s)

387-391

1 reference

Clinical course and risk factors of neurotoxicity following cisplatin in an intensive dosing schedule.

23 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900381-1

7 January 2021

The course of neuropathy after cessation of cisplatin treatment, combined with Org 2766 or placebo

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900381-1

7 January 2021

Incidence of neuropathy in 395 patients with ovarian cancer treated with or without cisplatin

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900381-1

7 January 2021

Peripheral sensory neuropathy and cisplatin chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900381-1

7 January 2021

Salvage chemotherapy for ovarian cancer recurrence: weekly cisplatin in combination with epirubicin or etoposide

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900381-1

7 January 2021

Response to salvage treatment in recurrent ovarian cancer treated initially with paclitaxel and platinum-based combination regimens

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900381-1

7 January 2021

Peripheral neurotoxicity induced by docetaxel.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900381-1

7 January 2021

Neurotoxicity is not enhanced by increased dose intensities of cisplatin administration.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900381-1

7 January 2021

Peripheral neuropathy induced by combination chemotherapy of docetaxel and cisplatin

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900381-1

7 January 2021

Prevention of cisplatin neurotoxicity with an ACTH(4-9) analogue in patients with ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900381-1

7 January 2021

Standardised method of determining vibratory perception thresholds for diagnosis and screening in neurological investigation

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900381-1

7 January 2021

Cisplatin neuropathy. Clinical, electrophysiologic, morphologic, and toxicologic studies.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900381-1

7 January 2021

Cisplatin neuropathy. Risk factors, prognosis, and protection by WR-2721.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900381-1

7 January 2021

High-dose cisplatin in patients with advanced malignancies.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900381-1

7 January 2021

Cis-diamminedichloroplatinum (II) by 5-day continuous infusion. A new dose schedule with minimal toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900381-1

7 January 2021

High-dose cisplatin in disseminated melanoma: a comparison of two schedules

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900381-1

7 January 2021

High-dose cisplatin in hypertonic saline: reduced toxicity of a modified dose schedule and correlation with plasma pharmacokinetics. A Northern California Oncology Group Pilot Study in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900381-1

7 January 2021

Mature results of a prospective randomized trial comparing a three-weekly with an accelerated weekly schedule of cisplatin in advanced ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900381-1

7 January 2021

Cisplatin-lnduced peripheral neurotoxicity is dependent on total-dose intensity and single-dose intensity

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900381-1

7 January 2021

Two sequential studies for primary peritoneal carcinoma: induction with weekly cisplatin followed by either cisplatin-doxorubicin-cyclophosphamide or paclitaxel-cisplatin

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900381-1

7 January 2021

Cerebral metastases: value of reirradiation in selected patients

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900381-1

7 January 2021

Outcome after spinal reirradiation for malignant epidural spinal cord compression.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900381-1

7 January 2021

10.1016/S0959-8049(01)00381-1

Identifiers

DOI

1 reference

23 July 2017

1 reference